Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Corcept Therapeutics Inc (NASDAQ: CORT) closed the day trading at $71.68 down -7.58% from the previous closing price of $77.56. In other words, the price has decreased by -$7.58 from its previous closing price. On the day, 6.06 million shares were traded.
Ratios:
For a better understanding of CORT, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 23.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 42.91. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 3.07. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on November 06, 2023, Upgraded its rating to Buy and sets its target price to $38 from $29 previously.
On April 11, 2023, SVB Securities started tracking the stock assigning a Market Perform rating and target price of $25.
On April 04, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on April 04, 2023, with a $27 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 02 ’25 when BELANOFF JOSEPH K bought 40,000 shares for $77.56 per share.
Maduck Sean bought 20,000 shares of CORT for $1,551,200 on Jun 02 ’25. On Jun 02 ’25, another insider, Lyon Joseph Douglas, who serves as the Officer of the company, bought 5,000 shares for $77.56 each.
Valuation Measures:
As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 62.22, and their Forward P/E ratio for the next fiscal year is 26.95. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.90. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.09 while its Price-to-Book (P/B) ratio in mrq is 11.12.
Stock Price History:
Over the past 52 weeks, CORT has reached a high of $117.33, while it has fallen to a 52-week low of $28.04. The 50-Day Moving Average of the stock is -0.15%, while the 200-Day Moving Average is calculated to be 26.11%.
Shares Statistics:
A total of 105.98M shares are outstanding, with a floating share count of 93.77M. Insiders hold about 11.58% of the company’s shares, while institutions hold 79.03% stake in the company.
Earnings Estimates
The current assessment of Corcept Therapeutics Inc (CORT) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.41, with high estimates of $0.46 and low estimates of $0.32.
Analysts are recommending an EPS of between $1.52 and $1.27 for the fiscal current year, implying an average EPS of $1.38. EPS for the following year is $2.66, with 4.0 analysts recommending between $3.96 and $1.12.
Revenue Estimates
4 analysts predict $199.39M in revenue for the current quarter. It ranges from a high estimate of $210M to a low estimate of $184.58M. As of the current estimate, Corcept Therapeutics Inc’s year-ago sales were $163.8MFor the next quarter, 4 analysts are estimating revenue of $247.54M. There is a high estimate of $261M for the next quarter, whereas the lowest estimate is $239.15M.
A total of 4 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $901.3M, while the lowest revenue estimate was $894.2M, resulting in an average revenue estimate of $899.05M. In the same quarter a year ago, actual revenue was $675.04MBased on 4 analysts’ estimates, the company’s revenue will be $1.22B in the next fiscal year. The high estimate is $1.38B and the low estimate is $1.03B.
